AN2 Therapeutics Total Assets Over Time
| ANTX Stock | USD 1.34 0.11 8.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out AN2 Therapeutics Performance and AN2 Therapeutics Correlation. AN2 |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AN2 Therapeutics. If investors know AN2 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AN2 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Return On Assets (0.43) | Return On Equity (0.69) |
The market value of AN2 Therapeutics is measured differently than its book value, which is the value of AN2 that is recorded on the company's balance sheet. Investors also form their own opinion of AN2 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is AN2 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AN2 Therapeutics' market value can be influenced by many factors that don't directly affect AN2 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AN2 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AN2 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AN2 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Assets Analysis
Compare AN2 Therapeutics and related stocks such as Aerovate Therapeutics, Adagene, and Acrivon Therapeutics, Total Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVTE | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 4.7 M | 175.4 M | 135.3 M | 127.4 M | 98.2 M |
| ADAG | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 105.9 M | 84.3 M | 189.5 M | 152.4 M | 115.7 M | 128.7 M |
| ACRV | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 106.6 M | 181.2 M | 138.3 M | 117.8 M |
| RZLT | 5.1 K | 5.1 K | 1.1 M | 7.4 M | 11.3 M | 10.9 M | 10.6 M | 2.5 M | 12.3 M | 11 M | 42.6 M | 152.4 M | 123.7 M | 132.7 M | 139.4 M |
| ANEB | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 21.7 M | 15.6 M | 11.7 M | 4.1 M | 3.9 M |
| MLYS | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 11.1 M | 114.4 M | 251.6 M | 264.2 M |
| MOLN | 110.1 M | 110.1 M | 110.1 M | 110.1 M | 194 M | 219.4 M | 184.1 M | 144.4 M | 155.2 M | 104.9 M | 187.5 M | 172.7 M | 262.3 M | 198.4 M | 193.3 M |
| PHVS | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 5.4 M | 20.6 M | 101.1 M | 212.1 M | 167.7 M | 398.7 M | 418.6 M |
| PEPG | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 10.6 M | 143.6 M | 217.4 M | 143.1 M | 114.2 M |
| PMVP | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 103 M | 365.5 M | 331.6 M | 270.3 M | 252.2 M | 254.1 M |
| MNOV | 8.4 M | 30.8 M | 19.6 M | 29.5 M | 27.3 M | 37.9 M | 39.8 M | 43.4 M | 77.2 M | 79.2 M | 75.4 M | 87.4 M | 74.2 M | 66.3 M | 62.3 M |
AN2 Therapeutics and related stocks such as Aerovate Therapeutics, Adagene, and Acrivon Therapeutics, Total Assets description
Total assets refers to the total amount of AN2 Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AN2 Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| AN2 Therapeutics | ANTX |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.34
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.